It must be kept in mind that anti-TNF agents do increase the risk of reactivation of tuberculosis, as well as pneumonia, and, as such, these conditions need to be ruled out and vaccinated against, respectively, before initiating these therapies [83]. The gene discussed is TNF; the disease is pneumonia.